Drugmakers Sanofi, Eli Lilly, Novo Nordisk and AstraZeneca must face a lawsuit from two health centers accusing them of ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Digitization has allowed Sanofi to optimize manufacturing and automate document preparation. And now, the firm predicts that ...

The study began on April 11, 2021, and was last updated on August 4, 2025. However, it has been terminated, which could impact the timeline for any potential market release of SAR444881.

Children with moderate/more extensive atopic dermatitis treated with ruxolitinib cream achieved significant disease control ...

U.S. sales of Eylea HD and Eylea, treatments for eye conditions like wet age-related macular degeneration, decrease 25% in ...

Sanofi Consumer Healthcare India reports ₹220 crore revenue, ₹60 crore profit, driven by exports, product launches, and ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

Sanofi Consumer Healthcare said its growth was driven by successful product launches and the successful relaunch of two ...

Paris Thursday, August 7, 2025, 10:00 Hrs [IST] Sanofi announces the completion of its acquisition of Vigil Neuroscience, I ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

Discover Novavax's Q2 2025 earnings insights: raised revenue targets, cost reductions, key partnerships with Sanofi & Takeda, and progress in ...